Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

Inclusion Criteria: * Ability to provide written informed consent and comply with the protocol. * At least 18 years of age. * Diagnosis of chronic atopic dermatitis for at least 3 years prior to enrollment. * Subject is considered a candidate for phototherapy or systemic therapy * Eczema Area and Severity Index (EASI) score ≥ 12 * Investigator Global Assessment (IGA) ≥ 3 * 10% body surface area (BSA) or greater * Subject is unlikely to conceive due to male, post-menopausal, or using adequate contraceptive (barrier, hormonal, implant, or permanent sterilization methods). * Physical exam within clinically acceptable limits. Exclusion Criteria: * Subject is unable to provide written informed consent or comply with the protocol. * Subject is younger than 18 years of age. * Subject has had atopic dermatitis for less than 3 years prior to enrollment. * Subject with mild atopic dermatitis (EASI\<12 and IGA\<3) or is not a candidate for phototherapy or systemic treatments. * Subject with current, or a history of, severe atopic dermatitis well controlled on current therapy. * Serious known infection. * History of immunosuppression (including human immunodeficiency virus (HIV)) * History of malignancy within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin. * Severe concomitant illnesses. * Having used immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.) or phototherapy within 4 weeks before the baseline visit. * Treatment with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit. * Treatment with any cell-depleting agents including but not limited to rituximab: within 6 months before the baseline visit, or until lymphocyte count returns to normal, whichever is longer, or use of other biologics: within 5 half-lives (if known) or 16 weeks prior to baseline visit, whichever is longer. * Physical or laboratory exam not within clinically acceptable limits. * Subjects possess other diagnoses that, in the investigator's opinion, preclude him/her from safely participating in this study or interfere with the evaluation of the subject's atopic dermatitis. * History of known or suspected intolerance to any of the ingredients of the investigational study product. * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>10 mIU/mL).